---
title: "CQP: As of the end of October, a total of RMB 80.9988 million has been spent to repurchase shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264034818.md"
description: "CQP announced that the company plans to repurchase shares in July 2025, with a total funding amount of 80 million to 100 million yuan, and the repurchase price not exceeding 6.6 yuan per share, with a duration of 12 months. As of October 31, the company has cumulatively repurchased 15.4066 million shares, accounting for 0.8915% of the total share capital, with a highest transaction price of 5.48 yuan per share and a lowest of 5.01 yuan per share, totaling a payment amount of 80.9988 million yuan. The company will continue to implement the repurchase according to the plan and disclose information in a timely manner"
datetime: "2025-11-03T13:15:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264034818.md)
  - [en](https://longbridge.com/en/news/264034818.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264034818.md)
---

# CQP: As of the end of October, a total of RMB 80.9988 million has been spent to repurchase shares

CQP announced that the company will repurchase shares in July 2025, with a total funding amount of 80 million to 100 million yuan, and the repurchase price not exceeding 6.6 yuan per share, with a duration of 12 months. As of October 31, the company has cumulatively repurchased 15.4066 million shares, accounting for 0.8915% of the total share capital, with a highest transaction price of 5.48 yuan per share and a lowest of 5.01 yuan per share, totaling a payment amount of 80.9988 million yuan. The company will continue to implement the repurchase according to the plan and disclose information in a timely manner

### Related Stocks

- [000950.CN](https://longbridge.com/en/quote/000950.CN.md)

## Related News & Research

- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)
- [Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29](https://longbridge.com/en/news/296393818.md)
- [Zephyr Introduces the Presrv™ Gourmet Clear Ice Machine](https://longbridge.com/en/news/296352842.md)
- [Hong Kong Gold Industry signs RMB 25.1 million automation control system contract for ilmenite mine plant upgrade](https://longbridge.com/en/news/296231100.md)
- [Konecranes wins order for 34 electric RTG cranes from APM Terminals Elizabeth](https://longbridge.com/en/news/296218206.md)